193 related articles for article (PubMed ID: 7705394)
1. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.
Brichard VG; Warnier G; Van Pel A; Morlighem G; Lucas S; Boon T
Eur J Immunol; 1995 Mar; 25(3):664-71. PubMed ID: 7705394
[TBL] [Abstract][Full Text] [Related]
2. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.
Maryanski JL; Van Snick J; Cerottini JC; Boon T
Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607
[TBL] [Abstract][Full Text] [Related]
5. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
[TBL] [Abstract][Full Text] [Related]
6. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
Van den Eynde B; Mazarguil H; Lethé B; Laval F; Gairin JE
Eur J Immunol; 1994 Nov; 24(11):2740-5. PubMed ID: 7525302
[TBL] [Abstract][Full Text] [Related]
7. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.
Lethé B; van den Eynde B; van Pel A; Corradin G; Boon T
Eur J Immunol; 1992 Sep; 22(9):2283-8. PubMed ID: 1381312
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
9. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1989 Feb; 30(2):323-9. PubMed ID: 2492486
[TBL] [Abstract][Full Text] [Related]
10. Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure.
Hiserodt JC
J Immunol; 1985 Jul; 135(1):53-62. PubMed ID: 3158707
[TBL] [Abstract][Full Text] [Related]
11. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
Yang G; Mizuno MT; Hellström KE; Chen L
J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
14. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
15. Requirements for CD28-dependent T cell-mediated cytotoxicity.
Azuma M; Cayabyab M; Phillips JH; Lanier LL
J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
[TBL] [Abstract][Full Text] [Related]
16. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
[TBL] [Abstract][Full Text] [Related]
17. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
18. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
19. Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL.
Silla S; Fallarino F; Boon T; Uyttenhove C
Eur Cytokine Netw; 1999 Jun; 10(2):181-90. PubMed ID: 10400824
[TBL] [Abstract][Full Text] [Related]
20. Specific lysis of murine cells expressing HLA molecules by allospecific human and murine H-2-restricted anti-HLA T killer lymphocytes.
Achour A; Begue B; Gomard E; Paul P; Sayagh B; Van Pel A; Levy JP
Eur J Immunol; 1986 Jun; 16(6):597-604. PubMed ID: 3522244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
